2020
Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou‐Alfa G. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. The Oncologist 2020, 26: e316-e326. PMID: 33021006, PMCID: PMC7873330, DOI: 10.1002/onco.13552.Peer-Reviewed Original ResearchConceptsSelective FGFR inhibitorsAdverse eventsDermatologic adverse eventsTyrosine kinaseFibroblast growth factor receptor tyrosine kinaseFGFR inhibitorsBladder cancerGrowth factor receptor tyrosine kinaseSkin eventsReceptor tyrosine kinasesPalmar-plantar erythrodysesthesia syndromeSelective fibroblast growth factor receptor (FGFR) inhibitorFibroblast growth factor receptor inhibitorManagement guidelinesGrowth factor receptor inhibitorsSkin adverse eventsTypical adverse eventsFrequent adverse eventsPossible adverse eventsEffective treatment strategiesBiological functionsEffective management plansQuality of lifeDermatologic eventsFGFR fusions
2019
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients